Skip to main content
Clinical Trials/NCT01763125
NCT01763125RecruitingNot Applicable

Establishment of a Blood Sample Bank in the Field of Gynaecological Oncology.

Medical University of Vienna6 sites in 4 countries10,000 target enrollmentStarted: November 2003Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
10,000
Locations
6
Primary Endpoint
Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.

Study Overview

Brief Summary

Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. The blood samples will be collected systematically together with the corresponding clinical data. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank.

Detailed Description

Recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to translational research. The relevance of "translational oncology" will only increase in the future -"From bench to bedside" - the swift implementation of new science research results in clinical studies in order to expedite progress in clinical cancer therapy for the benefit of the patient.

Its almost a matter of course in the medical science today to collect biological samples together with clinical information thereby creating the foundation for future excellent fundamental research.

The aim of this tumor bank is to consist of biological samples (together with a tissue bank - see EK 260/2003) and isolates of tumor patients and healthy people as controls. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank. The content of the tumor bank can provide essential material for current and future research (e.g. analyses of prognostic or predictive tumor markers; genetically analysis (polymorphism, mutation, hypermethylation; verification and characterisation of disseminated tumor cells).

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Male/Female
  • Age 18 to 90 years max.
  • Just one current known malignant disease or
  • Just one current inflammatory disease

Exclusion Criteria

  • Inflammatory disease and malignant disease
  • multiple malignancies
  • multiple diseases

Outcomes

Primary Outcomes

Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.

Time Frame: 14 years

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Robert Zeillinger, Dr.phil.

Prof. Dr.

Medical University of Vienna

Study Sites (6)

Loading locations...

Similar Trials